{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:55:16Z","timestamp":1776228916156,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Key Clinical Message<\/jats:title><jats:p>This case report and literature review examine the use of a relatively novel agent in a transfusion\u2010dependent beta\u2010thalassemia patient with extramedullary hematopoiesis (EMH). It examines the benefits and risks associated with its use and reviews the available literature while highlighting the drug's results in our patient with a higher risk profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>Beta thalassemia can be complicated by EMH, which causes different symptoms based on location and size. Luspatercept is a new agent approved for transfusion\u2010dependent thalassemia and Non\u2010transfusion\u2010dependent thalassemia (NTDT). Still, its use in patients with EMH was not well studied, and literature showed an increased risk of EMH expansion or development of new masses after its use. We discuss, in this case, the results of luspatercept treatment in a patient with transfusion\u2010dependent thalassemia who is considered high risk for its use due to the patient's specific characteristics (history of symptomatic intrathoracic EMH, previous splenectomy, refusal to use antithrombotic medications). While also highlighting the benefits of using luspatercept regarding decreasing the iron overload and improving hemoglobin levels and examining how it was used safely to manage a transfusion\u2010dependent thalassemia patient with an extramedullary hematopoiesis mass with no adverse events of note.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccr3.8795","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T02:04:18Z","timestamp":1715393058000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Luspatercept's use in a patient with transfusion\u2010dependent beta\u2010thalassemia and intrathoracic extramedullary hematopoiesis (EMH)"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-1831","authenticated-orcid":false,"given":"Mohammed Najdat","family":"Seijari","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Hamad General Hospital, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[{"name":"Hematology department Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hematology department Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243154"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2048065"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-022-00506-7"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2022.11.001"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1860003"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2017.018"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2048065"},{"issue":"1","key":"e_1_2_11_9_1","first-page":"45","article-title":"Extra\u2010medullary haematopoiesis in beta\u2010thalassaemia","volume":"51","author":"Habibzadeh F","year":"2005","journal-title":"J Postgrad Med"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18470"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029334"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v89i2-S.7086"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-9485.2012.02397.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908892"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002725"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31570"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122561"},{"issue":"325025","key":"e_1_2_11_18_1","first-page":"EP1305","article-title":"Long\u2010term efficacy and safety outcomes in the phase 2 study of luspatercept in \u03b2\u2010thalassemia","author":"Piga A","year":"2021","journal-title":"EHA Library Piga A"},{"key":"e_1_2_11_19_1","unstructured":"FDA Drug Safety\u2010related Labeling Changes (SrLC) REBLOZYL (BLA\u2010761136).2022Available form: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=2643."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.36"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03940.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases10040085"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910182"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.8795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T05:35:11Z","timestamp":1716960911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.8795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/ccr3.8795"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.8795","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e8795"}}